| Title |
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, February 2013
|
| DOI | 10.1007/s00280-013-2070-8 |
| Pubmed ID | |
| Authors |
J. L. Welsh, B. A. Wagner, T. J. van’t Erve, P. S. Zehr, D. J. Berg, T. R. Halfdanarson, N. S. Yee, K. L. Bodeker, J. Du, L. J. Roberts, J. Drisko, M. Levine, G. R. Buettner, J. J. Cullen |
| Abstract |
Treatment for pancreatic cancer with pharmacological ascorbate (ascorbic acid, vitamin C) decreases tumor progression in preclinical models. A phase I clinical trial was performed to establish safety and tolerability of pharmacological ascorbate combined with gemcitabine in patients with biopsy-proven stage IV pancreatic adenocarcinoma. |
X Demographics
The data shown below were collected from the profiles of 146 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 9 | 6% |
| United States | 5 | 3% |
| Micronesia, Federated States of | 2 | 1% |
| Belgium | 1 | <1% |
| United Kingdom | 1 | <1% |
| Canada | 1 | <1% |
| Malaysia | 1 | <1% |
| United Arab Emirates | 1 | <1% |
| Lithuania | 1 | <1% |
| Other | 1 | <1% |
| Unknown | 123 | 84% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 142 | 97% |
| Scientists | 2 | 1% |
| Practitioners (doctors, other healthcare professionals) | 2 | 1% |
Mendeley readers
The data shown below were compiled from readership statistics for 163 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Canada | 2 | 1% |
| Denmark | 1 | <1% |
| Unknown | 160 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 25 | 15% |
| Student > Master | 20 | 12% |
| Student > Bachelor | 18 | 11% |
| Other | 16 | 10% |
| Student > Ph. D. Student | 15 | 9% |
| Other | 36 | 22% |
| Unknown | 33 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 52 | 32% |
| Biochemistry, Genetics and Molecular Biology | 22 | 13% |
| Agricultural and Biological Sciences | 14 | 9% |
| Nursing and Health Professions | 8 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 4% |
| Other | 21 | 13% |
| Unknown | 39 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 142. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2023.
All research outputs
#291,988
of 25,462,162 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#5
of 2,564 outputs
Outputs of similar age
#2,075
of 291,690 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#1
of 33 outputs
Altmetric has tracked 25,462,162 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,564 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 291,690 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.